APLI:CC News and Press, Appili Therapeutics Inc. From 04/17/25

2025-04-17 10:15:00 ET Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100 , the lead therapeutic candidate from Aditxt’s ...

2025-04-16 09:15:00 ET Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received Institutional Review Board approval to initiate a clinical study evaluating the Mitomic Endometriosis Test (MET), a blood-based diagnostic aimed at early detection of endometriosis. The stu...

2025-04-14 09:35:00 ET Aditxt (NASDAQ: ADTX) announced that a Mayo Clinic-led study has validated preclinical findings for ADI-100, the lead autoimmune therapy candidate developed by its subsidiary Adimune Inc. The study confirmed ADI-100’s ability to induce immune tolerance to g...

2025-04-11 08:45:00 ET Aditxt (NASDAQ: ADTX) a social innovation platform focused on advancing health innovations, announced that its latest Aditxt Weekly Update will highlight several key developments. The Company recently received a notice from Nasdaq confirming it has regained compli...

2025-04-09 09:35:00 ET Aditxt (NASDAQ: ADTX) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), eliminating the need for a previously scheduled hearing with the exchange’s Hearings Panel. The company’s sto...

2025-04-02 09:15:00 ET Aditxt (NASDAQ: ADTX) , a social innovation platform accelerating health breakthroughs, announced that Don Cilla, Pharm.D., M.B.A., CEO of Appili Therapeutics, will join its Weekly Update on April 4 at 11:30 a.m. ET. The session will spotlight the growing need for...

Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Compan...

Event exploring the increasing risk of emerging infectious diseases Update on Appili transaction and recent operational highlights, including $117M submitted in federal funding applications Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platfo...

2025-03-28 09:35:00 ET Aditxt (NASDAQ: ADTX) , a social innovation platform focused on accelerating health technologies, announced that its latest Aditxt Weekly Update will spotlight the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The proprietary technolog...

The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University Aditxt, Inc. (...